Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don’t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium’s second SIRPαFc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRPα as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.